Recommendations for the use of cardiac troponin measurement in acute cardiac care

Kristian Thygesen, Johannes Mair, Hugo Katus, Mario Plebani, Per Venge, Paul Collinson, Bertil Lindahl, Evangelos Giannitsis, Yonathan Hasin, Marcello Galvani, Marco Tubaro, Joseph S Alpert, Luigi M. Biasucci, Wolfgang Koenig, Christian Mueller, Kurt Huber, Christian Hamm, Allan S. Jaffe

Research output: Contribution to journalArticle

431 Citations (Scopus)

Abstract

The release of cardiomyocyte components, i.e. biomarkers, into the bloodstream in higher than usual quantities indicates an ongoing pathological process. Thus, detection of elevated concentrations of cardiac biomarkers in blood is a sign of cardiac injury which could be due to supply-demand imbalance, toxic effects, or haemodynamic stress. It is up to the clinician to determine the most probable aetiology, the proper therapeutic measures, and the subsequent risk implied by the process. For this reason, the measurement of biomarkers always must be applied in relation to the clinical context and never in isolation. There are a large number of cardiac biomarkers, but they can be subdivided into four broad categories, those related to necrosis, inflammation, haemodynamic stress, and/or thrombosis. Their usefulness is dependent on the accuracy and reproducibility of the measurements, the discriminatory limits separating pathology from physiology, and their sensitivity and specificity for specific organ damage and/or disease processes. In recent years, cardiac biomarkers have become important adjuncts to the delivery of acute cardiac care. Therefore, the Working Group on Acute Cardiac Care of the European Society of Cardiology established a committee to deal with ongoing and newly developing issues related to cardiac biomarkers. The intention of the group is to outline the principles for the application of various biomarkers by clinicians in the setting of acute cardiac care in a series of expert consensus documents. The first of these will focus on cardiac troponin, a pivotal marker of cardiac injury/necrosis.

Original languageEnglish (US)
Pages (from-to)2197-2204
Number of pages8
JournalEuropean Heart Journal
Volume31
Issue number18
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Troponin
Biomarkers
Necrosis
Hemodynamics
Poisons
Wounds and Injuries
Pathologic Processes
Cardiac Myocytes
Consensus
Thrombosis
Pathology
Inflammation
Sensitivity and Specificity

Keywords

  • 99th percentile decision level
  • Cardiac biomarkers
  • Cardiac troponin I
  • Cardiac troponin T
  • Cardiac troponins
  • Myocardial infarction
  • Myocardial injury
  • Myocardial necrosis
  • Troponin assay impression
  • Troponin assays

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Thygesen, K., Mair, J., Katus, H., Plebani, M., Venge, P., Collinson, P., ... Jaffe, A. S. (2010). Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 31(18), 2197-2204. https://doi.org/10.1093/eurheartj/ehq251

Recommendations for the use of cardiac troponin measurement in acute cardiac care. / Thygesen, Kristian; Mair, Johannes; Katus, Hugo; Plebani, Mario; Venge, Per; Collinson, Paul; Lindahl, Bertil; Giannitsis, Evangelos; Hasin, Yonathan; Galvani, Marcello; Tubaro, Marco; Alpert, Joseph S; Biasucci, Luigi M.; Koenig, Wolfgang; Mueller, Christian; Huber, Kurt; Hamm, Christian; Jaffe, Allan S.

In: European Heart Journal, Vol. 31, No. 18, 09.2010, p. 2197-2204.

Research output: Contribution to journalArticle

Thygesen, K, Mair, J, Katus, H, Plebani, M, Venge, P, Collinson, P, Lindahl, B, Giannitsis, E, Hasin, Y, Galvani, M, Tubaro, M, Alpert, JS, Biasucci, LM, Koenig, W, Mueller, C, Huber, K, Hamm, C & Jaffe, AS 2010, 'Recommendations for the use of cardiac troponin measurement in acute cardiac care', European Heart Journal, vol. 31, no. 18, pp. 2197-2204. https://doi.org/10.1093/eurheartj/ehq251
Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal. 2010 Sep;31(18):2197-2204. https://doi.org/10.1093/eurheartj/ehq251
Thygesen, Kristian ; Mair, Johannes ; Katus, Hugo ; Plebani, Mario ; Venge, Per ; Collinson, Paul ; Lindahl, Bertil ; Giannitsis, Evangelos ; Hasin, Yonathan ; Galvani, Marcello ; Tubaro, Marco ; Alpert, Joseph S ; Biasucci, Luigi M. ; Koenig, Wolfgang ; Mueller, Christian ; Huber, Kurt ; Hamm, Christian ; Jaffe, Allan S. / Recommendations for the use of cardiac troponin measurement in acute cardiac care. In: European Heart Journal. 2010 ; Vol. 31, No. 18. pp. 2197-2204.
@article{e3fee1510f4d4dedbce08cc083fc2f37,
title = "Recommendations for the use of cardiac troponin measurement in acute cardiac care",
abstract = "The release of cardiomyocyte components, i.e. biomarkers, into the bloodstream in higher than usual quantities indicates an ongoing pathological process. Thus, detection of elevated concentrations of cardiac biomarkers in blood is a sign of cardiac injury which could be due to supply-demand imbalance, toxic effects, or haemodynamic stress. It is up to the clinician to determine the most probable aetiology, the proper therapeutic measures, and the subsequent risk implied by the process. For this reason, the measurement of biomarkers always must be applied in relation to the clinical context and never in isolation. There are a large number of cardiac biomarkers, but they can be subdivided into four broad categories, those related to necrosis, inflammation, haemodynamic stress, and/or thrombosis. Their usefulness is dependent on the accuracy and reproducibility of the measurements, the discriminatory limits separating pathology from physiology, and their sensitivity and specificity for specific organ damage and/or disease processes. In recent years, cardiac biomarkers have become important adjuncts to the delivery of acute cardiac care. Therefore, the Working Group on Acute Cardiac Care of the European Society of Cardiology established a committee to deal with ongoing and newly developing issues related to cardiac biomarkers. The intention of the group is to outline the principles for the application of various biomarkers by clinicians in the setting of acute cardiac care in a series of expert consensus documents. The first of these will focus on cardiac troponin, a pivotal marker of cardiac injury/necrosis.",
keywords = "99th percentile decision level, Cardiac biomarkers, Cardiac troponin I, Cardiac troponin T, Cardiac troponins, Myocardial infarction, Myocardial injury, Myocardial necrosis, Troponin assay impression, Troponin assays",
author = "Kristian Thygesen and Johannes Mair and Hugo Katus and Mario Plebani and Per Venge and Paul Collinson and Bertil Lindahl and Evangelos Giannitsis and Yonathan Hasin and Marcello Galvani and Marco Tubaro and Alpert, {Joseph S} and Biasucci, {Luigi M.} and Wolfgang Koenig and Christian Mueller and Kurt Huber and Christian Hamm and Jaffe, {Allan S.}",
year = "2010",
month = "9",
doi = "10.1093/eurheartj/ehq251",
language = "English (US)",
volume = "31",
pages = "2197--2204",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Recommendations for the use of cardiac troponin measurement in acute cardiac care

AU - Thygesen, Kristian

AU - Mair, Johannes

AU - Katus, Hugo

AU - Plebani, Mario

AU - Venge, Per

AU - Collinson, Paul

AU - Lindahl, Bertil

AU - Giannitsis, Evangelos

AU - Hasin, Yonathan

AU - Galvani, Marcello

AU - Tubaro, Marco

AU - Alpert, Joseph S

AU - Biasucci, Luigi M.

AU - Koenig, Wolfgang

AU - Mueller, Christian

AU - Huber, Kurt

AU - Hamm, Christian

AU - Jaffe, Allan S.

PY - 2010/9

Y1 - 2010/9

N2 - The release of cardiomyocyte components, i.e. biomarkers, into the bloodstream in higher than usual quantities indicates an ongoing pathological process. Thus, detection of elevated concentrations of cardiac biomarkers in blood is a sign of cardiac injury which could be due to supply-demand imbalance, toxic effects, or haemodynamic stress. It is up to the clinician to determine the most probable aetiology, the proper therapeutic measures, and the subsequent risk implied by the process. For this reason, the measurement of biomarkers always must be applied in relation to the clinical context and never in isolation. There are a large number of cardiac biomarkers, but they can be subdivided into four broad categories, those related to necrosis, inflammation, haemodynamic stress, and/or thrombosis. Their usefulness is dependent on the accuracy and reproducibility of the measurements, the discriminatory limits separating pathology from physiology, and their sensitivity and specificity for specific organ damage and/or disease processes. In recent years, cardiac biomarkers have become important adjuncts to the delivery of acute cardiac care. Therefore, the Working Group on Acute Cardiac Care of the European Society of Cardiology established a committee to deal with ongoing and newly developing issues related to cardiac biomarkers. The intention of the group is to outline the principles for the application of various biomarkers by clinicians in the setting of acute cardiac care in a series of expert consensus documents. The first of these will focus on cardiac troponin, a pivotal marker of cardiac injury/necrosis.

AB - The release of cardiomyocyte components, i.e. biomarkers, into the bloodstream in higher than usual quantities indicates an ongoing pathological process. Thus, detection of elevated concentrations of cardiac biomarkers in blood is a sign of cardiac injury which could be due to supply-demand imbalance, toxic effects, or haemodynamic stress. It is up to the clinician to determine the most probable aetiology, the proper therapeutic measures, and the subsequent risk implied by the process. For this reason, the measurement of biomarkers always must be applied in relation to the clinical context and never in isolation. There are a large number of cardiac biomarkers, but they can be subdivided into four broad categories, those related to necrosis, inflammation, haemodynamic stress, and/or thrombosis. Their usefulness is dependent on the accuracy and reproducibility of the measurements, the discriminatory limits separating pathology from physiology, and their sensitivity and specificity for specific organ damage and/or disease processes. In recent years, cardiac biomarkers have become important adjuncts to the delivery of acute cardiac care. Therefore, the Working Group on Acute Cardiac Care of the European Society of Cardiology established a committee to deal with ongoing and newly developing issues related to cardiac biomarkers. The intention of the group is to outline the principles for the application of various biomarkers by clinicians in the setting of acute cardiac care in a series of expert consensus documents. The first of these will focus on cardiac troponin, a pivotal marker of cardiac injury/necrosis.

KW - 99th percentile decision level

KW - Cardiac biomarkers

KW - Cardiac troponin I

KW - Cardiac troponin T

KW - Cardiac troponins

KW - Myocardial infarction

KW - Myocardial injury

KW - Myocardial necrosis

KW - Troponin assay impression

KW - Troponin assays

UR - http://www.scopus.com/inward/record.url?scp=77956943712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956943712&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehq251

DO - 10.1093/eurheartj/ehq251

M3 - Article

C2 - 20685679

AN - SCOPUS:77956943712

VL - 31

SP - 2197

EP - 2204

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 18

ER -